N-picolyl derivatives of Kemp's triamine as potential antitumor agents: A preliminary investigation

Journal of Medicinal Chemistry

Volumn 48, Issue 25, 2005, Pages 7993-7999

  Regino, Celeste Aida S ^a   Torti, Suzy V ^b   Ma, Rong ^b   Yap, Glenn P A ^d   Kreisel, Kevin A ^d   Torti, Frank M ^b   Planalp, Roy P ^c   Brechbiel, Martin W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c Univ of New Hampshire   (United States)

^d UNIVERSITY OF DELAWARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3,5 TRIAMINO 1,3,5 TRIMETHYLCYCLOHEXANE DERIVATIVE; ANTINEOPLASTIC AGENT; LIGAND; N PICOLYL DERIVATIVE; TACHPYR; TRENPYR; TRI(PICOLYL) DERIVATIVE; UNCLASSIFIED DRUG;

AMINATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HELA CELL; HUMAN; HUMAN CELL; IC 50; LIGAND BINDING; REDUCTION; STRUCTURE ANALYSIS;

ANTINEOPLASTIC AGENTS; CHELATING AGENTS; COPPER; CYCLOHEXANES; CYCLOHEXYLAMINES; DRUG SCREENING ASSAYS, ANTITUMOR; ETHYLENEDIAMINES; HELA CELLS; HUMANS; MOLECULAR STRUCTURE; ORGANOMETALLIC COMPOUNDS; PICOLINIC ACIDS; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; ZINC;

EID: 29144518552     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050724r     Document Type: Article

References (53)

1. Kaim, W.; Schwederski, B. Historical Background, Current Relevance and Perspectives. In Bioinorganic Chemistry: Inorganic Elements in the Chemistry of Life. An Introduction and Guide; John Wiley & Sons Ltd.: West Sussex, U.K., 1996; pp 1-5.
2. Beinert, H. Development of the Field and Nomenclature; Lovenberg, W., Horecker, B., Kaplan, N. O., Marmur, J., Scheraga, H. A., Eds.; Molecular Biology, An International Series of Monographs and Textbooks, Vol. 1; Academic Press: New York, 1973; pp 1-36.
3. Halliwell, B., Gutteridge, J. M. C., Eds. The Chemistry of Free Radicals and Related "Reactive Species". In Free Radicals in Biology and Medicine, 3rd ed.; Oxford University Press Inc.: New York, 1999; pp 36-104.
4. Deroche, A.; Morgenstern-Badarau, I.; Cesario, M.; Guilhem, J.; Keita, B.; Nadjo, L.; Houée-Levin, C. A seven-coordinate manganese(II) complex formed with a single tripodal heptadentate ligand as a new superoxide scavenger. J. Am. Chem. Soc. 1996, 118, 4567-4573.
5. Morgenstern-Badarau, I.; Lambert, F.; Renault, J. P.; Cesario, M.; Maréchal, J.-D.; Maseras, F. Amine conformational change and spin conversion induced by metal-assisted ligand oxidation: from the seven-coordinate iron(II)-TPAA complex to the oxidized iron(II)-(py)3 tren isomers. Characterization, crystal structures, and density functional study. Inorg. Chim. Acta 2000, 297, 338-350.
6. Hoselton, M. A.; Wilson, L. J.; Drago, R. S. Substituent effects on the spin equilibrium observed with hexadentate ligands on iron(II). J. Am. Chem. Soc. 1975, 97, 1722-1729.
7. Brittenham, G. M.; Weiss, G.; Brissot, P.; Lainê, F.; Guillygomarc'h, A.; Guyader, D.; Moirand, R.; Deugnier, Y. Clinical consequences of new insights in the pathophysiology of disorders of iron and heme metabolism. Am. Soc. Hematol. 2000, 39-50.
8. Cazzola, M.; Bergamaschi, G.; Dezza, L.; Arosio, P. Manipulation of cellular iron metabolism for modulating normal and malignant cell proliferation: Achievements and prospects. Blood 1990, 75, 1903-1919.
9. Richardson, D. R. Mysteries of the transferrin-transferrin receptor 1 interaction uncovered. Cell 2004, 116, 486-485.
10. Torti, S. V.; Planalp, R. P.; Brechbiel, M. W.; Park, G.; Torti, F. M. Iron Chelation in Cancer Therapy. In Molecular Biology of Hematopoiesin; Abraham, N., et al., Eds.; Kluwer Academic/Plenum Publishers: New York, 1999; Vol. 6, pp 381-389.
11. Lederman, H. M.; Cohen, A.; Lee, J. W. W.; Freedman, M. H.; Gelfand, E. W. Desferrioxamine: A reversible S-phase inhibitor of human lymphocyte proliferation. Blood 1984, 64, 748-753.
12. Hoffbrand, A. V.; Ganeshaguru, K.; Hooton, J. W. L.; Tattersall, M. H. N. Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells. Br. J. Hematol. 1976, 33, 517-526.
13. Brown, N. C.; Elliasson, R.; Reichard, P.; Thelander, L. Spectrum and iron content of protein B2 from ribonucleotide diphosphate reductase. Eur. J. Biochem. 1969, 9, 512.
14. Schafer, A. I.; Bunn, H. F. Iron-Deficiency and Iron-Loading Anemias. In Harrisons Principles of Internal Medicine, 10th ed.; Petersdorf, R. G., Adams, R. D., Braunwald, E., Isselbacher, K. J., Martin, J. B., Wilson, J. D., Eds.; McGraw-Hill Book Company: New York, 1983; pp 1848-1853.
15. Gao, J.; Richardson, D. R. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. IV: The mechanisms involved in inhibiting cell-cycle progression. Blood 2001, 98, 842-850.
16. Joynson, D. H. M.; Jacobs, A.; Murray-Walker, D.; Dolby, A. E. Defect of cell-mediated immunity in patients with iron-deficiency anaemia. Lancet 1972, 300, 1058-1059.
17. Robbins, E.; Pederson, T. Iron: Its intracellular localization and possible role in cell division. Proc. Natl. Acad. Sci. U.S.A. 1970, 66, 1244-1251.
18. Hill, R. S.; Petitt, J. E.; Tattersall, M. H. N.; Kiley, N.; Lewis, S. M. Iron deficiency and dyserythropoiesis. Br. J. Haematol. 1972, 23, 507-512.
19. Hershko, C. H.; Karsai, A.; Eylon, L.; Izak, G. The effect of chronic iron deficiency on some biochemical functions of the human hemopoietic tissue. Blood 1970, 36, 321-329.
20. van der Weyden, M.; Rother, M.; Firkin, B. Megaloblastic maturation masked by iron deficiency: A biochemical basis. Br. J. Haematol. 1972, 22, 299-307.
21. Brockman, R. W.; Shaddix, S.; Stringer, V.; Adamson, D. Enhancement by desferrioxamine of inhibition of DNA synthesis by ribonucleotide reductase inhibitors. Proc. Am. Assoc. Cancer Res. 1972, 13, 88.
22. Laster, W. R., Jr.; Brockman, R. W. Enhancement of the activity of 5-hydroxypyridine-2-carboxaldehyde thiosonicarbazone (HCT) by desferrioxamine mesylate (Desferal (R)) in vivo. Proc. Am. Assoc. Cancer Res. 1973, 14, 18.
23. Le, N. T. V.; Richardson, D. R. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim. Biophys. Acta 2002, 1603, 31-46.
24. Richardson, D. R. Analogues of pyridoxal isonicotinoyl hydrazone (PIH) as potential iron chelators for the treatment of neoplasia. Leuk. Lymphoma 1998, 31, 47-60.
25. Rakba, N.; Loyer, P.; Gilot, D.; Delcros, J. G.; Glaise, D.; Baret, P.; Piere, J. L.; Brissot, P.; Lescoat, G. Antiproliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines. Carcinogenesis 2000, 21, 943-951.
26. Aouad, F.; Florence, A.; Zhang, Y.; Collins, F.; Henry, C.; Wad, R. J.; Crichton, R. R. Evaluation of new iron chelators and their therapeutic potential. Inorg. Chim. Acta 2002, 339, 470-480.
27. Torti, S. V.; Torti, F. M.; Whitman, S. P.; Brechbiel, M. W.; Park, G.; Planalp, R. P. Tumor cell cytotoxicity of a novel metal chelator. Blood 1998, 92, 1384-1389.
28. Hann, H.-W. L.; Stahlhut, M. W.; Blumberg, B. S. Iron nutrition and tumor growth: Decreased tumor growth in iron-deficient mice. Cancer Res. 1988, 48, 4168-4170.
29. Blatt, J.; Stitely, S. Antineuroblastoma activity of desferrioxamine in human cell lines. Cancer Res. 1987, 47, 1749-1750.
30. Becton, D. L.; Bryles, P. Desferioxamine inhibition of human neuroblastoma viability and proliferation. Cancer Res. 1988, 48, 7189-7192.
31. Donfrancesco, A.; Deb, G.; Dominici, C.; Ieggi, D.; Castello, M. A.; Helson, L. Effects of a single course of desferioxamine in neuroblastoma patients. Cancer Res. 1990, 50, 4929-4930.
32. Donfrancesco, A.; Deb, G.; Dominici, C. Desferioxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECaD: A new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma. Am. J. Clin. Oncol. 1992, 15, 319-322.
33. Donfrancesco, A.; de Bernardi, B.; Carli, M. Desferioxamine (D) followed by cytoxan (C), etoposide (E), carboplatin (Ca), thio-TEPA (T), induction regimen in advanced neuroblastoma. Eur. J. Cancer 1995, 31A, 612-615.
34. Richardson, D. R. Analogues of pyridoxal isonicotinoyl hydrazone (PIH) as potential iron chelators for the treatment of neoplasia. Leuk. Lymphoma 1998, 31, 47-60.
35. Abeysinghe, R. D.; Greene, B. T.; Haynes, R.; Willingham, M. C.; Turner, J.; Planalp, R. P.; Brechbiel, M. W.; Torti, F. M.; Torti, S. V. p53-Independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Carcinogenesis 2001, 22, 1607-1614.
36. Park, G.; Lu, F. H.; Ye, N.; Brechbiel, M. W.; Torti, S. V.; Torti, F. M.; Planalp, R. P. Novel iron complexes and chelators based on cis,cis-1,3,5-triaminocyclohexane: iron-mediated ligand oxidation and biochemical properties. J. Biol. Inorg. Chem. 1998, 3, 449-457.
37. 2 (M = Zn, Cd and Hg). Polyhedron 2000, 19, 1155-1161.
38. Hancock, R. D.; Martell, A. E. Ligand design for selective complexation of metal ions in aqueous solution. Chem. Rev. 1989, 89, 1875-1914.
39. Busch, D. H. The compleat coordination chemistry-one practioner's perspective. Chem. Rev. 1993, 93, 847-860.
40. Hou, Z.; Stack, T. D. P.; Sunderland, C. J.; Raymond, K. N. Enhanced iron(III) chelation through ligand predisposition: syntheses, structures and stability of tris-catecholate enterobactin analogs. Inorg. Chim. Acta 1997, 263, 341-355.
41. Menger, F. M.; Bian, J.; Azov, V. A. A 1,3,5-triaxial triaminocyclohexane: The triamine corresponding to Kemp's triacid. Angew. Chem., Int. Ed. 2002, 41, 2581-2584.
42. Bowen, T.; Planalp, R. P.; Brechbiel, M. W. An improved synthesis of cis,cis-1,3,5-triaminocyclohexane. Synthesis of novel hexadentate ligand derivatives for the preparation of gallium radiopharmaceuticals. Bioorg. Med. Chem. Lett. 1996, 6, 807-810.
43. Menger, F. M.; Ladika, M. Fast hydrolysis of an aliphatic amide at neutral pH and ambient temperature: A peptidase model. J. Am. Chem. Soc. 1988, 110, 6794-6796.
44. Borch, R.; Durst, H. D. Lithium cyanohydridoborate, a versatile new reagent. J. Am. Chem. Soc. 1969, 91, 3996-3997.
45. Borch, R. F.; Bernstein, M. D.; Durst, H. D. The cyanohydridoborate anion as a selective reducing agent. J. Am. Chem. Soc. 1971, 93, 2897-2904.
46. Fleischer, E. B.; Gebala, A. E.; Swia, D. R.; Tasker, P. A. Trigonal prismatic-octahedral coordination. Complexes of intermediate geometry. Inorg. Chem. 1972, 11, 2775-2784.
47. Park, G.; Dadachova, E.; Przyborowska, A.; Lai, S.; Ma, D.; Broker, G.; Rogers, R. D.; Planalp, R. P.; Brechbiel, M. W. Synthesis of novel 1,3,5-cis,cis-triaminocyclohexane ligand based Cu (II) complexes as potential radiopharmaceuticals and correlation of structure and serum stability. Polyhedron 2001, 20, 3155-3163.
48. Bondi, A. van der Waals volumes and radii. J. Phys. Chem. 1964, 68, 441-451.
49. 3, M = Ga, In) of N,N′,N″-tris(2-pyridylmethyl)-cis- 1,3,5-triaminocyclohexane: Preparation and structure. Inorg. Chem. 1997, 36, 4600-4603.
50. Sheldrick, G. M. SADABS Adsorption Corrections Program; Bruker-AXS, 2001.
51. Vandersluis, P.; Spek, A. L. Bypass, an effective method for the refinement of crystal structures containing disordered solvent regions. Acta Crystallogr., Sect. A 1990, 46, 194-201.
52. Sheldrick, G. M. SHELXTL, version 6.12 program library; Bruker-AXS, 2001.
53. Mossman, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55-63.